Therapeutic development typically originates from cellular and animal models, leading to a remarkable attrition rate due to the ‘translational’ gap between laboratory findings and patients. Immetas’ strategy begins with clinical data, including from human genetic disorders and clinical trials involving the relevant targets; by matching molecular profiling of the target pathways with disease signatures; and by applying statistical algorithms to explore disease pathology and outcomes. Integrating such clinical data at the front end of drug discovery is designed to mitigate this development risk.